The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
The company impresses investors, but money’s running short.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.